Large Cell Carcinoma of the Lung
by Adele Shenoy MD and Charles L. Fishman, MD
Large-cell carcinomas are a diagnosis of exclusion when a lung malignancy does not meet the criteria of small-cell lung cancer (SCLC), adenocarcinoma, or squamous-cell carcinoma based on light microscopy and immunohistochemical-marker expression.
Large-cell carcinomas are aggressive and represent about 5%-10% of lung cancers. Histologically, they are malignant epithelial neoplasms (poorly differentiated) without glandular or squamous differentiation or small-cell features.
Causes and Risk Factors
Smoking is the primary risk factor for all lung cancers, including large-cell carcinoma. The median age of presentation is 61 years; men are three times more likely than women to develop these cancers.
Read the full In Brief for more about:
Signs and Symptoms
Diagnostic Evaluation and Differential Diagnosis
and a summary of Lung Cancer Classification
Members can read the full Large Cell Carconima of the Lung In Brief on FibonacciMD.app
Not an APP member? Membership info.
Travis WD, Brambilla EW, Burke AP, Marx A, Nicholson AG, eds. WHO Classification of Tumours of the Lung, Pleura, Thymus, and Heart. Lyon, France: IARC Press; 2015.
Clinical Lung Cancer Genome Project; Network Genomic Medicine. A genomics-based classification of human lung tumors. Sci Transl Med. 2013;5(209):209ra153.
Rajdev K, Hasan Siddiqui A, Ibrahim U, Patibandla P, Khan T, El-Sayegh D. An unusually aggressive large cell carcinoma of the lung: undiagnosed until autopsy. Cureus. 2018;10:e2202.
Derks J, Hendriks L, Buikhuisen W, Groen H, Thunnissen E, Van Suylen RJ, Houben R, Damhuis R, Speel E, Dingemans AM. Clinical features of large cell neuroendocrine carcinoma: a population-based overview. European Respiratory Journal 2016 47: 615-624; DOI: 10.1183/13993003.00618-2015.
Limaiem F, Tariq M, Wallen J. Lung Carcinoid Tumors. StatPearls. Last Update: October 16, 2020.
Pulmonary Neuroendocrine Tumors. Memorial Sloan Kettering Cancer Center. https://www.mskcc.org/cancer-care/types/lung/types/pulmonary-neuroendocrine-tumors.
ABOUT THE AUTHORS
Chuck Fishman, M.D.
Dr. Fishman is an assistant professor of medicine at the Columbia University Irving Medical Center in New York, and is a diplomate of the American Board of Internal Medicine in Pulmonary disease. He has been a practicing pulmonologist for 26 years. He completed residency and chief residency in Internal Medicine at Montefiore Medical Center in the Bronx, NY, and fellowship training in Pulmonary and Critical Care Medicine at New York University-Bellevue Medical Center. Prior to this, he completed his undergraduate studies at the University of Pennsylvania, and received his MD degree from the Mount Sinai School of Medicine. His hobbies include snow shoeing, pickleball, and serving in the leadership of his Synagogue.
Adele Shenoy, M.D.
Dr. Shenoy graduated from New York Medical College and is currently a first year resident in Internal Medicine at Mount Sinai West/Mount Sinai Morningside. She will begin her Dermatology residency at Northwell next year. A native of Westport, Connecticut. Dr. Shenoy completed her undergraduate education at Dartmouth College. Her hobbies include running, ballet, and playing the viola.
LEARN MORE SCIENCE
Click here to see more on Squamous Cell Carcinoma of the Lung
IMIT takes pride in its work, and the information published on the IMIT Platform is believed to be accurate and reliable. The IMIT Platform is provided strictly for informational purposes, and IMIT recommends that any medical, diagnostic, or other advice be obtained from a medical professional. Read full disclaimer.